Abbvie Inc Shares Close in on 52-Week High - Market Mover
The shares closed 0.2% below its 52-week high of $167.95, with trading volume lower than its 30 day average
Feb 01, 2024 by Kwhen Finance Editors
Abbvie Inc (ABBV) shares closed today at 0.2% below its 52 week high of $167.95, giving the company a market cap of $295B. The stock is currently up 6.8% year-to-date, up 16.6% over the past 12 months, and up 166.5% over the past five years. This week, the Dow Jones Industrial Average rose 0.9%, and the S&P 500 rose 1.6%.
Trading Activity
- Trading volume this week was 3.9% lower than the 20-day average.
- Beta, a measure of the stock’s volatility relative to the overall market stands at 0.2.
Technical Indicators
- The Relative Strength Index (RSI) on the stock was between 30 and 70.
- MACD, a trend-following momentum indicator, indicates a downward trend.
- The stock closed above its Bollinger band, indicating it may be overbought.
Fundamentals & Catalysts
- Over the past 12 months the company generated $21 billion in earnings before interest and taxes from $50 billion in revenue. It currently holds $9 billion in cash and $31 billion in debt.
- Its forward price-to-earnings (P/E) ratio of 0 is lower than its current P/E ratio of 45.54, implying that analysts are expecting an increase in earnings.
- The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at -0.81. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
- The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 10.98 which means it currently has $10.98 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
- The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 14.58. This means that the stock is trading at a premium of 15 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
- The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 3.98.
- The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 5.49.
P/E
45.54
EBITDA
$21B
P/Book
14.58
Mkt Cap
$295B
P/Sales
3.98
Revenue
$50B
EPS (TTM)
3.65
PEG Ratio
-0.81
EV/Revenue
5.49
Total Cash
$9B
Debt/Equity
10.98
Forward P/E
0.00
Current Debt
$31B
Gross Profit
$32B
Dividend Date
-
Earnings Date
2024-02-02
Profit Margin
0.10
Revenue/Share
28.42
Total Revenue
$50B
Enterprise Val
$275B
Put/Call Ratio
0.86
Revenue/Employee
1673166.67
Market Comparative Performance
- The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis
- The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis
- The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis
| Name | DoD %Δ | YTD %Δ | 1 Yr % | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|
| Abbvie Inc | 1.9 | 6.8 | 16.6 | -3.0 | 28.3 |
| Dow Jones Industrial Average | 1.0 | 1.8 | 15.9 | -0.5 | 24.2 |
| S&P 500 Index | 1.3 | 3.4 | 23.8 | -1.4 | 30.2 |
| Health Care | 1.2 | 2.8 | 7.9 | -0.8 | 15.9 |
Peer Group Comparative Performance
- The company's stock price performance year-to-date beats the peer average by 190.0%
- The company's stock price performance over the past 12 months beats the peer average by 57.3%
- The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 23.9% higher than the average peer.
| Name | MKT CAP (USD) | P/E | YTD %Δ | 1 Yr %Δ | 52-Week H % | 52-Week L % |
|---|---|---|---|---|---|---|
| Abbvie Inc | ABBV | 45.5 | 6.8 | 16.6 | -3.0 | 28.3 |
| Peer Avg | N/A | 36.8 | 2.3 | 10.5 | -7.8 | 15.8 |
| Lilly(Eli) & Co | LLY | 122.7 | 10.6 | 90.4 | -0.4 | 110.0 |
| Astrazeneca plc - ADR | AZN | 35.3 | -0.2 | 5.4 | ||
| AMGEN Inc. | AMGN | 22.2 | 8.8 | 28.9 | ||
| Pfizer Inc. | PFE | 14.8 | -3.1 | -34.0 | -36.1 | 6.4 |
| Bristol-Myers Squibb Co. | BMY | 12.2 | -1.7 | -28.5 | -32.6 | 2.3 |
| Gilead Sciences, Inc. | GILD | 16.8 | -2.4 | 0.9 | ||
| Glaxosmithkline plc - ADR | GSK | 9.0 | 5.4 | 15.1 | -1.1 | 23.8 |
| Biogen Inc | BIIB | 24.5 | -4.3 | -14.7 | ||
| Neurocrine Biosciences, Inc. | NBIX | 73.2 | 7.9 | 31.4 |
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.
Was this content valuable for you?
Tags: